
|Videos|April 25, 2014
PD-L1 Expression in Non-Clear Cell Renal Cell Cancer
Author(s)David F. McDermott, MD
David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses PD-L1 expression in non-clear cell kidney cancer.
Advertisement
David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses PD-L1 expression in non-clear cell kidney cancer.
Clinical Pearls:
- In the past, it was thought that immune therapies worked better in clear-cell kidney cancer compared to non-clear cell kidney cancer
- A study found that non-clear cell tumors expressed PD-L1 on their tumor surface, begging the question if these patients might respond to PD-1 or PD-L1 antibodies
- Patients with non-clear cell tumors should be included in future trials that include PD-1 or PD-L1 antibodies
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















